EGFR (Epidermal growth factor receptor)

P1/2, N=27, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: May 2030 --> Dec 2029 | Trial primary completion date: Jun 2027 --> Jan 2027

Several FAK targeted inhibitors have advanced into clinical evaluation; for example, CEP-37440 is undergoing phase I trials, whereas GSK-2256098 has reached phase II trials. This review summarizes the structure and functional characteristics of FAK, its role in the pathogenesis of NSCLC, the research progress on FAK inhibitors, and the current status and prospects of combining FAK inhibitors with other therapies for NSCLC. The aim is to provide new insights for future clinical trial design and combination therapy strategies for NSCLC.

Additional barriers, including limited access to LC screening and the underrepresentation of women in clinical trials, further constrain the application of evidence-based interventions for women. This review synthesizes latest evidence on epidemiology, risk factors, molecular features, screening, treatment outcomes, and survivorship challenges in women with LC with a deep focus on novel approaches to overcome current barriers and disparities to improve prevention, early detection, treatment, and long-term survivorship care.

The clinical development of this combination strategy was discontinued, as brigatinib treatment was not feasible in patients with advanced EGFR-mutated NSCLC resistant to osimertinib.

Moreover, several types of radionuclides possess 'cross-fire' effects that result in the eradication of neighbouring tumour cells lacking the biomarker expression. In the current review, we summarise the potential biomarkers for the development of RT and TRT that can be employed in the treatment of BC, including receptor markers of ER, PR and HER2, together with other markers of Trop2, PD-1, EGFR, GRPR and PSMA.

The expanding role of NGS enables personalized postoperative strategies, including tailored follow-up intervals and potential circulating tumor DNA monitoring to detect minimal residual disease. In summary, incorporating broad molecular testing in early-stage NSCLC empowers clinicians to optimize adjuvant treatment decisions and surveillance strategies, ultimately aiming to improve patient outcomes through precision oncology.

Moreover, they demonstrated high accuracy in identifying cases lacking alterations. Our results highlight the potential of deep-learning tools for the detection of NSCLC biomarkers and specifically the identification of tumors without EGFR or ALK driver alterations, supporting more informed clinical decision-making.

Baseline circulating tumor DNA (ctDNA) variant allele frequency predicts ctDNA clearance at cycle 3 day 1, which correlates with longer PFS. Double-dose firmonertinib shows promising efficacy and tolerability, supporting its preliminary potential as first-line treatment for EGFR L858R-mutated advanced NSCLC.

Molecular dynamics simulations supported baicalein-TOP2A complex stability. These findings reveal QLXZD exerts anti-PCa effects via a multi-component, multi-target mechanism, supporting its clinical application.